Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Pediatr Infect Dis J ; 42(3): e61-e63, 2023 03 01.
Article in English | MEDLINE | ID: covidwho-2253399

ABSTRACT

Children affected by coronavirus disease 2019 (COVID-19) with preexisting comorbidities are at risk of complications. Monoclonal antibodies prevent severe COVID-19 courses in adults but data on children are scarce. Here we report on the use of Sotrovimab in 14 children at risk of severe disease treated at the University of Cologne Children's Hospital. Tolerability was good and no infusion-related reactions were seen.


Subject(s)
COVID-19 , Adult , Child , Humans , Antibodies, Monoclonal, Humanized , Antibodies, Monoclonal , Antibodies, Neutralizing
2.
J Infect Dis ; 2022 Feb 16.
Article in English | MEDLINE | ID: covidwho-2272042

ABSTRACT

The aim of this retrospective analysis was to provide information on how infections with RSV and SARS-CoV-2 differ in symptoms, clinical course, outcome and the utilization of hospital care. We investigated 748 PCR results from symptomatic children aged 0 - 4 years in Cologne, Germany. 169 patients were tested positive for RSV (22.6%) and 24 children for SARS-CoV-2 (3.2%). Symptomatic patients with RSV-infection were hospitalized significantly longer. RSV-positive patients needed O2-supplementation significantly more often as well as High Flow-therapy. With regard to care efforts, RSV-infected patients put higher pressure on the hospital and utilized more hospital resources.

3.
Viruses ; 14(8)2022 07 23.
Article in English | MEDLINE | ID: covidwho-1957456

ABSTRACT

Almost two and a half years after the appearance of the first cases of SARS-CoV-2 in December 2019, more than 500 million people have been infected with SARS-CoV-2 and over 6 million have died of it worldwide. In terms of the pediatric cohort, it already became evident at an early stage that the infection causes milder symptoms in children and rarely runs a fatal course. OBJECTIVE: This work presents data gathered over a period of over two years in patients between the age of 0 and 18 years. The aim is to provide information on the clinical aspects of the five different SARS-CoV-2 waves. METHODS: Between 13 March 2020 and 22 April 2022, all nucleic acid amplification tests (NAATs) of children who received a swab for SARS-CoV-2 at our clinic were included. Data were collected on standardized questionnaires. The analysis of the data was anonymized and retrospective. RESULTS: We investigated 21,635 NAATs, of which 1028 of the tests were positive (4.8%). The highest rate of positive results was observed in the fifth wave (541/2.292 NAATs (23.6%)). Most of the children who were hospitalized were hospitalized in wave three (22.9%). The availability of a vaccine was followed by a decrease in positive NAATs in the corresponding age group thereafter. CONCLUSIONS: These data underline the fact that children infected with SARS-CoV-2, regardless of which VOC, are often only mildly affected. Vaccinations seem to remain the key to avoid massive numbers of infected people and a potential collapse of the healthcare systems.


Subject(s)
COVID-19 , SARS-CoV-2 , Adolescent , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19 Testing , Child , Child, Preschool , Germany/epidemiology , Humans , Infant , Infant, Newborn , Retrospective Studies , SARS-CoV-2/genetics
4.
Nat Commun ; 13(1): 3640, 2022 06 25.
Article in English | MEDLINE | ID: covidwho-1908167

ABSTRACT

Systematic SARS-CoV-2 testing is a valuable tool for infection control and surveillance. However, broad application of high sensitive RT-qPCR testing in children is often hampered due to unpleasant sample collection, limited RT-qPCR capacities and high costs. Here, we developed a high-throughput approach ('Lolli-Method') for SARS-CoV-2 detection in children, combining non-invasive sample collection with an RT-qPCR-pool testing strategy. SARS-CoV-2 infections were diagnosed with sensitivities of 100% and 93.9% when viral loads were >106 copies/ml and >103 copies/ml in corresponding Naso-/Oropharyngeal-swabs, respectively. For effective application of the Lolli-Method in schools and daycare facilities, SEIR-modeling indicated a preferred frequency of two tests per week. The developed test strategy was implemented in 3,700 schools and 698 daycare facilities in Germany, screening over 800,000 individuals twice per week. In a period of 3 months, 6,364 pool-RT-qPCRs tested positive (0.64%), ranging from 0.05% to 2.61% per week. Notably, infections correlated with local SARS-CoV-2 incidences and with a school social deprivation index. Moreover, in comparison with the alpha variant, statistical modeling revealed a 36.8% increase for multiple (≥2 children) infections per class following infections with the delta variant. We conclude that the Lolli-Method is a powerful tool for SARS-CoV-2 surveillance and can support infection control in schools and daycare facilities.


Subject(s)
COVID-19 , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19 Testing , Child , Clinical Laboratory Techniques/methods , Humans , SARS-CoV-2/genetics , Sensitivity and Specificity
5.
Viruses ; 13(8)2021 08 12.
Article in English | MEDLINE | ID: covidwho-1355051

ABSTRACT

In May 2021, the Alpha variant (B.1.1.7) of SARS-CoV-2 was found in 91% of the SARS-CoV-2 cases in Germany. Not much is known about the symptoms, courses of disease, and infectiousness in pediatric patients with the Alpha variant. OBJECTIVE: The aim of this retrospective analysis was to gain information on the infection with the Alpha variant in children and adolescents. METHODS: Between 12 January 2021 and 3 June 2021, all nucleic acid amplification tests (NAATs) of children who received a swab for SARS-CoV-2 were included. Data were collected on standardized questionnaires. The analysis of data was anonymized and retrospective. RESULTS: We investigated 3544 NAATs; 95 children were tested positive (2.7%) for SARS-CoV-2. For the sub-analysis, 65 children were analyzed. In 59 children, the Alpha variant was found (90.8%), and 54.2% (n = 32/59) were symptomatic. The most common symptoms were fever, cough, and rhinitis. The median Ct value was 24.0 (min 17.0; max 32.7). CONCLUSIONS: We can underline early findings that children are still less effected by SARS-CoV-2 infection with the spread of the Alpha variant. We found no evidence that children infected with the Alpha variant showed more severe symptoms or suffered from a more severe clinical course than those infected with the wild type.


Subject(s)
COVID-19/epidemiology , COVID-19/virology , SARS-CoV-2 , Adolescent , COVID-19/diagnosis , COVID-19/physiopathology , COVID-19 Nucleic Acid Testing , Child , Child, Preschool , Cough , Fever , Germany/epidemiology , Humans , Infant , Mutation , Nucleic Acid Amplification Techniques , Retrospective Studies , SARS-CoV-2/genetics
SELECTION OF CITATIONS
SEARCH DETAIL